| Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies (NCT04776850) | M.D. Anderson Cancer Center | 2020-12-29 |
| ERN-EuroBloodNet Registry on Patients With Rare Red Blood Cell Defects and COVID-19 (NCT06831799) | Hospital Universitari Vall d'Hebron Research Institute | 2020-04-15 |
| Phase 2a Pilot Study of NBMI Treatment in Patients With Beta Thalassemia Major, Requiring Iron Chelation (NCT04092205) | EmeraMed | 2019-11-21 |
| T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias (NCT03653338) | Paul Szabolcs | 2018-08-02 |
| PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders (NCT04353986) | Ain Shams University | 2018-06-11 |
| Gene Therapy for Beta-Thalassemia Major Using Autologous Hematopoietic Stem Cell Genetically Modified (NCT03276455) | Nanfang Hospital, Southern Medical University | 2017-09-15 |
| Monitoring of Chimerism After Transplantation in Patients With β Thalassemia Major and the Treatment Strategies for the Reduction of Chimerism (NCT03101423) | First Affiliated Hospital of Guangxi Medical University | 2016-08-01 |
| Effect of Spirulina on Serum Hyaluronic Acid in Beta Thalassemic Children With Hepatitis C (NCT02744547) | Tanta University | 2015-12-01 |
| the Potential Immunomodulatory Effects of Spirulina on Thalassemic Children (NCT02674607) | Tanta University | 2015-10-01 |
| Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major (NCT02342145) | Zhongming Zhang | 2015-04-01 |
| Effect of Spirulina Compared to Amlodipine on Cardiac Iron Overload in Children With Beta Thalassemia (NCT02671695) | Tanta University | 2015-04-01 |
| Effect of Spirulina on Liver Iron Concentration in Beta Thalassemic Children With Hepatitis C (NCT02744560) | Tanta University | 2015-03-01 |
| An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients (NCT02173951) | Ain Shams University | 2014-07-01 |
| A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease (NCT02151526) | Genetix Biotherapeutics Inc. | 2013-06-07 |
| Anthropometric Measurements in Children Having Transfusion-dependent Beta Thalassemia (NCT03947632) | Aga Khan University | 2013-01-01 |
| Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia. (NCT01571635) | Celgene | 2012-10-10 |
| Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload (NCT01511848) | Ain Shams University | 2012-02-01 |
| Therapeutic Effects of Silymarin in Patients With B-thalassemia Major (NCT00999349) | Isfahan University of Medical Sciences | 2009-03-01 |
| HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity (NCT02435901) | Northwell Health | 2008-12-01 |
| Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major (NCT00658385) | Memorial Sloan Kettering Cancer Center | 2008-04-01 |
| Clinical Trial of Deferasirox Combination Treatment With Deferiprone In Thalassaemia Patients (NCT02198508) | China Medical University Hospital | 2007-07-01 |
| Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration) (NCT00171301) | Novartis Pharmaceuticals | 2005-06-01 |